

Case Docket No. AVANIR.079RX

Date: January 17, 2002

Page 1

# ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Sir:

Transmitted herewith for filing is the reissue application of

Inventors:

Richard Alan Smith and Jonathan M. Licht

For:

DEXTROMETHORPHAN AND AN OXIDASE INHIBITOR FOR

TREATING INTRACTABLE CONDITIONS

#### Enclosed are:

- (X) Preliminary Amendment;
- (X) A copy of U.S. Patent No. 5,863,927, as originally issued, including the specification, claims, and drawings as required;
- (X) Reissue Application Declaration by the Assignee;
- (X) Reissue Application Consent of Assignee;
- (X) Statement Under 37 C.F.R. §3.73(b);
- (X) Establishment of Right of Assignee to Take Action and Revocation and Power of Attorney;
- (X) Offer to Surrender Under 37 C.F.R. §1.178;
- (X) This application qualifies for Small Entity Status;
- (X) Return prepaid postcard;
- (X) A check in the amount of \$370.00 to cover the filing fee is enclosed;
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment to Account No. 11-1410.

Mark/R. Benedict

Registration No. 44,531

Attorney of Record

H:\DOCS\MRB\MRB-2797.DOC\aef 011702

#### STATEMENT UNDER 37 C.F.R. §3.73(b)

Applicant/Patent Owner: Center for Neurologic Study, La Jolla, California

Patent Number: 5,863,927

Date Issued: January 26, 1999

Title: DEXTROMETHORPHAN AND AN OXIDASE INHIBITOR FOR TREATING INTRACTABLE CONDITIONS

Center for Neurologic Study, a not-for-profit foundation, states that it is the assignee of the entire right, title, and interest in the patent identified above by virtue of an assignment from the inventors of the patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 9068, Frame 0121.

Full name person signing: Richard Alan Smith

Signature / Cirhard	alanc	tmill

Title: DIRECTOR

H:\DOCS\PTH\AVANIR.079RX\STATEMENT UNDER 37 CFR 3.73.DOC 101101

# OFFER TO SURRENDER 37 C.F.R. §1.178

## ASSISTANT COMMISSIONER FOR PATENTS:

The undersigned applicant of the accompanying reissue application for the reissue of letters Patent No. 5,863,927 for an improvement in DEXTROMETHORPHAN AND AN OXIDASE INHIBITOR FOR TREATING INTRACTABLE CONDITIONS, granted on January 26, 1999 to Smith et al., hereby offers to surrender said letters patent.

Cirlard Alan Smith

1/9/02

Date

H:\DOCS\PTH\AVANIR.079RX\OFFER TO SURRENDER.DOC 101101

01/18/02

# **Knobbe Martens Olson & Bear LLP**

Intellectual Property Law

620 Newport Center Drive Sixteenth Floor Newport Beach, CA 92660 Tel 949-760-0404 Fax 949-760-9502 www.kmob.com

Mark R. Benedict, Ph.D. 949-721-6323 mbenedict@kmob.com

#### **BOX REISSUE**

Assistant Commissioner for Patents Washington, D.C. 20231

### CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Attorney Docket No. :

AVANIR.079RX

**Applicants** 

Smith, et al.

For

DEXTROMETHORPHAN AND AN

OXIDASE INHIBITOR FOR TREATING

INTRACTABLE CONDITIONS

Attorney

Mark R. Benedict

"Express Mail"

Mailing Label No.

EV 037394969 US

**Date of Deposit** 

January 18, 2002

### I hereby certify that the accompanying

Transmittal letter; Preliminary Amendment in 3 pages; Copy of U.S. Patent No. 5,863,927 in 11 pages; Reissue Application Declaration by the Assignee in 2 pages; Reissue Application Consent of Assignee in 1 page; Statement Under 37 C.F.R. §3.73(b) in 1 page; Establishment of Right of Assignee to Take Action and Revocation and Power of Attorney in 2 pages; Offer to Surrender in 1 page; Small Entity Statement; Check for Filing Fee in the amount of \$370.00; Return Prepaid Postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Jose Colunga

H:\DOCS\MRB\MRB-2802\aef

San Diego 619-235-8550 San Francisco 415-954-4114 Los Angeles 310-551-3450 Riverside 909-781-9231